These findings are encouraging for drug-resistant CRC, which is resistant to anti-EGFR biologics such as cetuximab due to ‘persister’ cells, but new evidence suggests combo therapy of cetuximab with pharmacologic dosing of ascorbate impairs the emergence of persister cells, limits growth of CRC organoids, and significantly delays acquired resistance by triggering adenosine triphosphate depletion and oxidative stress resulting in ferroptotic cell death.63 This evidence concerns the gene EGFR and colorectal carcinoma.